Clinical study of sindilimab combined with docetaxel for second-line treatment of advanced gastric cancer
Objective To investigate the efficacy and safety of sindilimab combined with docetaxel as second-line treatment of advanced gastric cancer.Methods From July 2020 to July 2022,23 patients with advanced gastric cancer who failed to first-line chemotherapy(platinum combined with fluorouracil)were treated with sindilimab combined with docetaxel.The primary endpoint was progression free survival(PFS),and secondary endpoints were overall survival(OS),disease control rate(DCR),objective response rate(ORR),and adverse reactions.Results A total of 23 patients were evaluated.Among them,6 cases were partial response,13 patients with stable disease,4 patients with progressive disease;the ORR was 26.1％and the DCR was 82.6％.The median PFS was 4.5 months.The median OS was 9.8 months.Cox multivariate analysis showed that peritoneal metastasis(HR=0.067,95％CI:0.006-0.696,P=0.024)was an independent risk factor for OS.The common adverse reactions were leukopenia,neutropenia,thrombocytopenia,anemia,nausea,vomiting,alopecia,peripheral neurotoxicity,abnormal liver function,and hypothyroidism.However most of these adverse events were grade 1 or 2.Conclusion Sindilimab combined with docetaxel for second-line treatment of advanced gastric cancer was safe and effective,and it should be worthy of clinical promotion.
NETL
NSTL
万方数据
